Terms: = Liver cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802 AND Treatment
204 results:
1. Validation of Core Ingredients and Molecular Mechanism of Cinobufotalin Injection Against liver cancer.
Chen S; Li M; Xue C; Zhou X; Wei J; Zheng L; Duan Y; Deng H; Tang F; Xiong W; Xiang B; Zhou M
Drug Des Devel Ther; 2024; 18():1321-1338. PubMed ID: 38681206
[TBL] [Abstract] [Full Text] [Related]
2. cdk4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma.
Cheng K; Zhou Z; Chen Q; Chen Z; Cai Y; Cai H; Wu S; Gao P; Cai Y; Zhou J; Wang X; Wu Z; Peng B
Sci Rep; 2024 Apr; 14(1):8389. PubMed ID: 38600093
[TBL] [Abstract] [Full Text] [Related]
3. First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Yarchoan M; Powderly JD; Bastos BR; Karasic TB; Crysler OV; Munster PN; McKean MA; Emens LA; Saenger YM; Ged Y; Stagg R; Smith S; Whiting CC; Moon A; Prasit P; Jenkins Y; Standifer N; Dubensky TW; Whiting SH; Ulahannan SV
Cancer Res Commun; 2024 Apr; 4(4):1100-1110. PubMed ID: 38551394
[TBL] [Abstract] [Full Text] [Related]
4. treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor-positive, HER2-negative metastatic breast cancer: A real-world multicenter study.
Li D; Jin Y; Lin M; Zeng C; Guo Q; Liu Y; Zhang J
Cancer Med; 2024 Feb; 13(4):e6762. PubMed ID: 38457252
[TBL] [Abstract] [Full Text] [Related]
5. Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC.
Yang J; Choi J; Choi WM; Kim KM; Lee HC; Shim JH
Liver Int; 2024 Apr; 44(4):907-919. PubMed ID: 38291863
[TBL] [Abstract] [Full Text] [Related]
6. Cepharanthine suppresses proliferation and metastasis and enhances apoptosis by regulating JAK2/Stat3 pathway in hepatocellular carcinoma.
Liang Y; Li J; Xu H; Pang M; Hu C; Weng X; Xie W
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):94-100. PubMed ID: 38279472
[TBL] [Abstract] [Full Text] [Related]
7. [Bone Marrow Carcinomatosis with Disseminated Intravascular Coagulation in a Breast cancer Patient Treated with Chemotherapy and cdk4/6 Inhibitor].
Kume S; Makino T; Goto A; Onodera Y; Kudo S
Gan To Kagaku Ryoho; 2023 Dec; 50(12):1331-1333. PubMed ID: 38247075
[TBL] [Abstract] [Full Text] [Related]
8. SNRPB promotes the progression of hepatocellular carcinoma via regulating cell cycle, oxidative stress, and ferroptosis.
Wang X; Zhang H; Guo Z; Wang J; Lu C; Wang J; Jin R; Mo Z
Aging (Albany NY); 2024 Jan; 16(1):348-366. PubMed ID: 38189879
[TBL] [Abstract] [Full Text] [Related]
9. SPINK1-induced tumor plasticity provides a therapeutic window for chemotherapy in hepatocellular carcinoma.
Man KF; Zhou L; Yu H; Lam KH; Cheng W; Yu J; Lee TK; Yun JP; Guan XY; Liu M; Ma S
Nat Commun; 2023 Nov; 14(1):7863. PubMed ID: 38030644
[TBL] [Abstract] [Full Text] [Related]
10. Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast cancer: A Retrospective Analysis of the MONARCH 2 Trial.
Gerratana L; Kocherginsky M; Davis AA; D'Amico P; Reduzzi C; Puglisi F; Cristofanilli M
Oncologist; 2024 Feb; 29(2):123-131. PubMed ID: 37935631
[TBL] [Abstract] [Full Text] [Related]
11. liver toxicity with ribociclib in a patient with metastatic hormone receptor positive postmenopausal breast cancer.
Sozer Karadagli S; Gursoy P
J Oncol Pharm Pract; 2024 Mar; 30(2):404-407. PubMed ID: 37899576
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).
Masuda J; Sakai H; Tsurutani J; Tanabe Y; Masuda N; Iwasa T; Takahashi M; Futamura M; Matsumoto K; Aogi K; Iwata H; Hosonaga M; Mukohara T; Yoshimura K; Imamura CK; Miura S; Yamochi T; Kawabata H; Yasojima H; Tomioka N; Yoshimura K; Takano T
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37709297
[TBL] [Abstract] [Full Text] [Related]
13. cdk4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis.
Behrouzi R; Armstrong AC; Howell SJ
Breast Cancer Res Treat; 2023 Nov; 202(1):83-95. PubMed ID: 37584881
[TBL] [Abstract] [Full Text] [Related]
14. Successful continuance of cdk4/6 inhibitor treatment with palbociclib after abemaciclib-induced hepatotoxicity in breast cancer: a case report.
Ozawa Y; Fujimiya T; Shimada A; Okazawa A; Kusano J; Yamamoto R; Hyasashi S
Anticancer Drugs; 2024 Jan; 35(1):89-92. PubMed ID: 37578747
[TBL] [Abstract] [Full Text] [Related]
15. Artichoke as a melanoma growth inhibitor.
Mathew AM; Deng Z; Nelson CJ; Mayberry TG; Bai Q; Lequio M; Fajardo E; Xiao H; Wakefield MR; Fang Y
Med Oncol; 2023 Aug; 40(9):262. PubMed ID: 37544953
[TBL] [Abstract] [Full Text] [Related]
16. Incidence and Features of Lymphoid Proliferation and Lymphomas after Solid Organ or Hematopoietic Stem Cell Transplantation in a National Database Cohort.
Hahn SM; Lee M; Hyun J; Lim S; Kang JM; Ahn JG; Joo DJ; Jung I; Ihn K
Cancer Res Treat; 2024 Jan; 56(1):305-313. PubMed ID: 37475137
[TBL] [Abstract] [Full Text] [Related]
17. Construction of a hepatocytes-related and protein kinase-related gene signature in HCC based on ScRNA-Seq analysis and machine learning algorithm.
Zhang Z; Mou L; Pu Z; Zhuang X
J Physiol Biochem; 2023 Nov; 79(4):771-785. PubMed ID: 37458958
[TBL] [Abstract] [Full Text] [Related]
18. Clinical and Genomic Characteristics of Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors.
Rao X; Chen Y; Beyrer J; Nash Smyth E; Morato Guimaraes C; Litchfield LM; Bowman L; Lawrence GW; Aggarwal A; Andre F
Clin Cancer Res; 2023 Sep; 29(17):3372-3383. PubMed ID: 37289194
[TBL] [Abstract] [Full Text] [Related]
19. Toxic hepatitis in metastatic breast cancer patient using ribociclib and denosumab.
Bayram D; Aktürk Esen S; Uçar G; Köş FT
J Oncol Pharm Pract; 2023 Sep; 29(6):1494-1497. PubMed ID: 37170613
[TBL] [Abstract] [Full Text] [Related]
20. Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4/6 inhibitors: a case report.
Yoneto T; Hasumi K; Takahashi N; Seki N; Takeda Y; Yoshimoto T
J Med Case Rep; 2023 May; 17(1):190. PubMed ID: 37158934
[TBL] [Abstract] [Full Text] [Related]
[Next]